Morepen Secures Fourth Consecutive USFDA Inspection with Zero Observations (NIL 483)

Morepen Laboratories announced the successful completion of a USFDA inspection at its API manufacturing facility in Masulkhana, Himachal Pradesh.

The inspection concluded with no adverse observations (NIL Form 483), indicating full compliance with US regulatory standards.

This marks the fourth consecutive clean USFDA inspection for the company over the past eight years.

Regulatory Excellence:

• USFDA inspection completed with zero observations
• Compliance with ICH and CFR (Part 21) guidelines
• Strong quality management and data integrity systems

Global Market Position:

• Strong presence in US, Europe, and other regulated markets
• Exports to 80+ countries
• Enhances credibility with global pharma clients

Business Impact:

• Improves eligibility for long-term supply contracts
• Strengthens positioning in CDMO and API segments
• Supports growth in regulated, high-margin markets

Operational Strength:

• Investments in digital systems, automation, and data integrity
• Ensures traceability, transparency, and efficiency

Note: Clean inspections are critical for sustaining exports to regulated markets like the US.

Key Risks

• Future inspections may not maintain the same outcome
• High dependency on regulated market approvals
• Pricing pressure in global API markets
• Regulatory tightening impacting compliance costs

Worst Case Scenario

Any adverse observation in future inspections could impact exports and client trust

Risk Level: Low

• Consistent NIL 483 track record reflects strong quality systems
• Enhances credibility with regulators and global customers
• Supports long-term contract opportunities
• Focus on digital transformation and compliance excellence